Niagen Bioscience, Inc. (NASDAQ: NAGE) is a bioscience company focused on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging, and its news flow reflects that specialization. Company announcements frequently highlight developments around its patented nicotinamide riboside ingredient Niagen®, the Tru Niagen® consumer supplement line, and the Niagen Plus™ intravenous and injectable platform.
Readers following NAGE news can expect updates on product launches and line extensions, such as Tru Niagen Beauty, which combines Niagen with clinically studied ingredients to support the appearance of hair, skin, and nails. News items also cover commercial partnerships and distribution milestones, including the expansion of pharmaceutical-grade Niagen Plus IV and injections into hundreds of clinics and wellness centers across the United States.
Because Niagen Bioscience emphasizes evidence-based positioning, a significant portion of its news relates to clinical and scientific progress. This includes publication of randomized controlled trials using Niagen in specific populations, summaries of peer-reviewed research on NAD+ biology, and the evolution of educational platforms like AboutNAD®, which curates NAD+ research for consumers, clinicians, and scientists.
Investors and observers will also find regular coverage of financial and corporate developments, such as quarterly earnings releases, changes to full-year outlook, share repurchase authorizations, and intellectual property transactions involving core nicotinamide riboside patents. For anyone tracking the NAD+ category, the NAGE news page offers an ongoing view into how Niagen Bioscience advances its science, expands its product ecosystem, and manages its capital and IP strategy. Bookmark this page to monitor new studies, product initiatives, and regulatory or market updates that the company discloses over time.
Niagen Bioscience (NAGE) will participate in Canaccord Genuity’s Well Summit in New York from September 28–30, 2026, with CEO Rob Fried and CFO Ozan Pamir attending.
Rob Fried is scheduled to speak on the “Aging on Trial: Peptides, Hormones, and the Line Between Breakthrough and Hype” panel on Tuesday, September 29, from 11:15 a.m. to 12:00 p.m. ET at The Plaza. A replay of the panel webcast will be made available on the Niagen Bioscience investor relations website after the event. The company highlights its focus on NAD+ science, its Niagen-powered Tru Niagen consumer supplement, and its Niagen Plus pharmaceutical-grade IV and injectable products.
Niagen Bioscience (NAGE) will participate in the Longevity Investors Conference, held September 14–17, 2026 in Gstaad, Switzerland.
CEO Rob Fried is scheduled to speak on the panel “Longevity Goes Mainstream: The Investment Case for Consumer Health” on Wednesday, September 16, from 14:50 to 15:30 CEST. Fried and CFO & Head of Business Development Ozan Pamir will also hold in-person one-on-one meetings with investors during the event. Attendees can sample the company’s Tru Niagen supplement and experience Niagen Plus on-site. Contact information is provided for investors who wish to arrange meetings with the management team.
Niagen Bioscience (NASDAQ: NAGE) announced that senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, at Nasdaq’s San Francisco office. The event will feature 25 curated public companies, each giving a 15-minute presentation followed by a 15-minute breakout session with institutional investors.
Niagen Bioscience CFO Ozan Pamir is scheduled to present at 11:20 a.m. PT, followed by a breakout session and availability for one-on-one meetings with institutional investors. Investors can request meetings via their conference representative or by emailing Niagen@KCSA.com. Niagen Bioscience describes itself as a global authority in NAD+ science with a clinically tested product portfolio centered on Niagen, which powers its Tru Niagen consumer supplement and Niagen Plus pharmaceutical-grade IV and injectable products.
Niagen Bioscience (NASDAQ: NAGE) announced that its Tru Niagen® NAD-boosting healthy-aging supplement is now available at nearly 300 GNC and Sam’s Club locations across 44 U.S. states, as well as on the retailers’ e-commerce platforms.
GNC offers Tru Niagen Beauty and 300mg 30-count bottles, while Sam’s Club sells 300mg 120-count bottles. According to Niagen Bioscience, Tru Niagen is powered by patented Niagen® (nicotinamide riboside), is clinically shown to increase NAD+ levels, and is backed by more than 45 human clinical studies, over 500 scientific publications, and over 60 patents worldwide.
Niagen Bioscience (NASDAQ: NAGE) announced that senior management will present at the 17th Annual Midwest IDEAS Investor Conference on Thursday, August 27, 2026, at The InterContinental Chicago. CFO Ozan Pamir is scheduled to present from 2:40–3:15 PM CT in Presenting Room 2 and will be available for one-on-one meetings with institutional investors.
The presentation will be livestreamed via the conference host’s website. Niagen Bioscience describes itself as a global authority in NAD+ healthy aging science, built around its patented Niagen ingredient, which powers Tru Niagen consumer supplements and Niagen Plus pharmaceutical-grade IV and injectable products, alongside R&D on therapies for accelerated aging and rare genetic diseases.
Niagen Bioscience (NASDAQ: NAGE) announced that its flagship healthy-aging NAD+ supplement Tru Niagen is now available on Walmart.com. The initial assortment includes Tru Niagen 300 mg in 30-count and 90-count bottles, with additional products expected to roll out over the coming weeks.
According to Niagen Bioscience, Tru Niagen is clinically shown to increase and sustain NAD+ levels and is powered by Niagen (patented nicotinamide riboside, NR). The company highlights backing from more than 45 human clinical studies, over 500 published scientific studies, and more than 50 patents. Citing Walmart data, Niagen points to Walmart’s growing digital scale, including approximately $27.1 billion in U.S. e-commerce net sales and $16.4 billion in U.S. health and wellness net sales in the quarter ended April 30, 2026.
Niagen Bioscience (NASDAQ:NAGE) reported Q2 2026 net sales of $29.8 million (vs. $31.1 million in Q2 2025), including $24.2 million from Tru Niagen. Direct-to-consumer website sales grew 23% year-over-year. Gross margin was 64.8%, with net income of $1.0 million ($0.01 per basic and diluted share) and adjusted EBITDA of $3.0 million.
For the first half of 2026, operating cash flow totaled $1.6 million, and cash and equivalents were $66.7 million. The company repurchased $2.8 million of stock. It launched the Niagen Plus telehealth platform, obtained LegitScript certification for at-home injection kits, and introduced NB4168, an oral NR prodrug for Ataxia-Telangiectasia, which received FDA Rare Pediatric Disease and EMA Orphan designations. Evotec was engaged for preclinical and IND-enabling studies, expected to begin in Q3 2026. Niagen guided 2026 e-commerce growth of 10%–15% and signaled higher operating expenses for strategic investments.
Niagen Bioscience (NASDAQ: NAGE) has selected Evotec (NASDAQ: EVO; FSE: EVT) as contract research organization to advance preclinical development of NB4168, an oral small-molecule candidate for Ataxia Telangiectasia (A-T). Evotec will run pharmacokinetic, pharmacodynamic and bioanalytical studies at its Verona, Italy campus using its INDiGO platform.
According to Niagen Bioscience, nonclinical data show substantially higher blood exposure for NB4168 versus NR chloride. NB4168 has received U.S. FDA Rare Pediatric Disease Designation and EMA Orphan Medicinal Product Designation for A-T. The company is progressing IND-enabling work and plans to submit an IND to begin human clinical studies.
Niagen Bioscience (NASDAQ: NAGE) reported a newly published peer-reviewed analysis in Aging Cell of three prior human studies and in vitro work evaluating Niagen® nicotinamide riboside (NR) on skeletal muscle epigenetic aging. The pooled analysis used seven established epigenetic clocks, including the muscle-specific MEAT clock, to measure epigenetic age acceleration (EAA), a biomarker of biological aging.
According to Niagen Bioscience, five-month supplementation with 1,000 mg/day Niagen NR in a twin study was associated with roughly a 2.5-year reduction in muscle EAA by the MEAT clock, with statistically significant EAA reductions also seen in DunedinPACE and PCHannum. Overall, six of seven skeletal muscle clocks shifted toward lower EAA, while one (PCGrimAge) increased. Blood-based clocks showed three significant EAA reductions. In cultured human myotubes, Niagen NR increased NAD+ levels 1.52-fold versus control without significant epigenetic-age or mitochondrial DNA changes, suggesting whole‑body factors may mediate in vivo effects. The company highlights these data as evidence that Niagen NR may influence muscle aging biomarkers and supports further research alongside exercise interventions.
Niagen Bioscience (NASDAQ: NAGE) announced that CEO Rob Fried and CFO Ozan Pamir will participate in Canaccord Genuity’s 46th Annual Growth Conference in Boston from August 11–13, 2026. Fried will join a fireside chat on Tuesday, August 11, at 2:00 p.m. ET, accessible via webcast registration at Summitcast, with a replay available on the Niagen Bioscience investor relations website.
According to Niagen Bioscience, management will also hold one-on-one meetings with institutional investors. The company highlights its NAD+-boosting portfolio, including Tru Niagen and Niagen Plus, and ongoing research under NAD Pharmaceuticals on its NB4168 molecule.